Cancer Radiotherapie最新文献

英文中文

RadioTransNet: Preclinical research network coordinated by the Société française de radiothérapie oncologique and Société française de physique médicale, 2025 update RadioTransNet：由Societe francaise de Radiotherapie Oncologique和Societe francaise de体质medicale协调的临床前研究网络，2025年更新。

IF 1.4 4区医学 Q4 ONCOLOGY

Cancer Radiotherapie

Pub Date : 2025-11-01 DOI: 10.1016/j.canrad.2025.104764

Émilie Bayart , Marc Benderitter , François Boussin , Jacques Balosso , Éric Deutsch , Élizabeth Cohen Jonathan-Moyal , Thomas Lacornerie , Sophie Pinel , Yolanda Prezado , Charlotte Robert , Stéphane Supiot , Grégory Delpon , Céline Bourgier

The RadioTransNet program, led by the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) in association with the Société française de physique médicale (SFPM, the French society of medical physics), certified by the Institut du cancer (INCa, the French national cancer institute), was created at the end of 2018. The aim is to create a coherent, national, and multidisciplinary structure for preclinical and translational research in oncological radiotherapy by identifying research priorities. Its activities are coordinated by a scientific council, composed of radiation oncologists-therapists, medical physicists and academic radiobiologists researchers, and organized around four major axes which are: the definition of target volumes, the interaction of ionizing radiation with tissues, combined treatments and modern approaches to dose calculation. These four major axes are associated with different objectives concerning basic radiobiology, the studies of implementation of new drugs in preclinical settings, the contribution of imaging and new tracers, research in medical physics, by integrating a cross-cutting dimension of medical oncology and cost/effectiveness considerations. The selected themes form the basis for the projects studied and developed, taking into account the complementary skills of all the partner platforms involved in the network. Orientation proposals based on the priorities selected by the scientific council are submitted to INCa for the opening of dedicated calls to finance the human and technical resources necessary to conduct, under the best conditions, preclinical and translational research in radiotherapy.

由法国放射肿瘤学学会（SFRO）与法国医学物理学会（SFPM）联合领导的RadioTransNet计划于2018年底创建，经法国国家癌症研究所（INCa）认证。目的是通过确定研究重点，为肿瘤放疗的临床前和转化研究创建一个连贯的、全国性的多学科结构。它的活动由一个科学委员会协调，该委员会由放射肿瘤学家-治疗师、医学物理学家和学术放射生物学家研究人员组成，并围绕四个主要轴进行组织：靶体积的定义、电离辐射与组织的相互作用、联合治疗和剂量计算的现代方法。这四个主要轴与以下方面的不同目标相关：基础放射生物学、临床前新药物实施研究、成像和新示踪剂的贡献、医学物理学研究，通过整合医学肿瘤学的跨领域维度和成本/效益考虑。选定的主题构成了研究和开发项目的基础，同时考虑到网络中涉及的所有伙伴平台的互补技能。根据科学理事会选定的优先事项向INCa提交方向建议，以开放专门呼吁，为在最佳条件下进行放射治疗临床前和转化研究所需的人力和技术资源提供资金。

{"title":"RadioTransNet: Preclinical research network coordinated by the Société française de radiothérapie oncologique and Société française de physique médicale, 2025 update","authors":"Émilie Bayart , Marc Benderitter , François Boussin , Jacques Balosso , Éric Deutsch , Élizabeth Cohen Jonathan-Moyal , Thomas Lacornerie , Sophie Pinel , Yolanda Prezado , Charlotte Robert , Stéphane Supiot , Grégory Delpon , Céline Bourgier","doi":"10.1016/j.canrad.2025.104764","DOIUrl":"10.1016/j.canrad.2025.104764","url":null,"abstract":"<div><div>The RadioTransNet program, led by the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) in association with the Société française de physique médicale (SFPM, the French society of medical physics), certified by the Institut du cancer (INCa, the French national cancer institute), was created at the end of 2018. The aim is to create a coherent, national, and multidisciplinary structure for preclinical and translational research in oncological radiotherapy by identifying research priorities. Its activities are coordinated by a scientific council, composed of radiation oncologists-therapists, medical physicists and academic radiobiologists researchers, and organized around four major axes which are: the definition of target volumes, the interaction of ionizing radiation with tissues, combined treatments and modern approaches to dose calculation. These four major axes are associated with different objectives concerning basic radiobiology, the studies of implementation of new drugs in preclinical settings, the contribution of imaging and new tracers, research in medical physics, by integrating a cross-cutting dimension of medical oncology and cost/effectiveness considerations. The selected themes form the basis for the projects studied and developed, taking into account the complementary skills of all the partner platforms involved in the network. Orientation proposals based on the priorities selected by the scientific council are submitted to INCa for the opening of dedicated calls to finance the human and technical resources necessary to conduct, under the best conditions, preclinical and translational research in radiotherapy.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104764"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145607890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

External beam radiotherapy for prostatic cancers: 2025 update 前列腺癌的外束放疗：2025年更新

IF 1.4 4区医学 Q4 ONCOLOGY

Cancer Radiotherapie

Pub Date : 2025-11-01 DOI: 10.1016/j.canrad.2025.104777

Igor Latorzeff , Alizée Camps-Maléa , Christophe Hennequin , Olivier Chapet , David Pasquier , Gilles Créhange , Pascal Pommiet , Renaud de Crevoisier , Pierre Blanchard , Ulrike Schicke , Vincent Marchesi , Paul Sargos , Stéphane Supiot

This article reports on the updated recommendations of the Société française de radiothérapie oncologique on external radiotherapy for prostate cancer. External radiotherapy is aimed for all localized prostate cancers, and more recently at oligometastatic prostate cancers. Irradiation techniques are detailed according to different risk levels. Prostate image-guided intensity-modulated radiotherapy is the recommended technique for these cancers. A total dose of 74 to 80 Gy is recommended for standard fractionation (delivered in 2 Gy fractions). Moderate hypofractionation (delivering a total dose of 60 Gy at a rate of 3 Gy per fraction over 4 weeks) in the prostate has become a therapeutic standard. Extreme hypofractionation (delivering 35 to 40 Gy in five fractions) to treat the prostate without pelvis, using a technique under stereotactic conditions, can be considered a recent standard in favourable and intermediate risk disease. The postoperative irradiation technique, mainly indicated in cases of biochemical recurrence and lymph node involvement, is described in detail. Recommendations concerning contouring and dosimetry are also provided.

本文报道了法国放射学会关于前列腺癌外放射治疗的最新建议。外放射治疗的目标是所有局限性前列腺癌，最近越来越多地用于少转移性前列腺癌。辐照技术根据不同的危险程度加以详细说明。前列腺图像引导的调强放疗是治疗这些癌症的推荐技术。建议标准分馏的总剂量为74至80 Gy（以2 Gy的分量递送）。在前列腺中进行适度的低分割（在4周内以每分割3戈瑞的速率给予总剂量为60戈瑞）已成为一种治疗标准。在立体定向条件下使用一种技术治疗无骨盆前列腺的极端低分割（分5次输送35 - 40 Gy），可被认为是有利和中等危险疾病的最新标准。详细介绍了术后放疗技术，主要适用于生化复发和淋巴结受累的病例。还提供了有关轮廓和剂量测定的建议。

{"title":"External beam radiotherapy for prostatic cancers: 2025 update","authors":"Igor Latorzeff , Alizée Camps-Maléa , Christophe Hennequin , Olivier Chapet , David Pasquier , Gilles Créhange , Pascal Pommiet , Renaud de Crevoisier , Pierre Blanchard , Ulrike Schicke , Vincent Marchesi , Paul Sargos , Stéphane Supiot","doi":"10.1016/j.canrad.2025.104777","DOIUrl":"10.1016/j.canrad.2025.104777","url":null,"abstract":"<div><div>This article reports on the updated recommendations of the Société française de radiothérapie oncologique on external radiotherapy for prostate cancer. External radiotherapy is aimed for all localized prostate cancers, and more recently at oligometastatic prostate cancers. Irradiation techniques are detailed according to different risk levels. Prostate image-guided intensity-modulated radiotherapy is the recommended technique for these cancers. A total dose of 74 to 80Gy is recommended for standard fractionation (delivered in 2Gy fractions). Moderate hypofractionation (delivering a total dose of 60Gy at a rate of 3Gy per fraction over 4weeks) in the prostate has become a therapeutic standard. Extreme hypofractionation (delivering 35 to 40Gy in five fractions) to treat the prostate without pelvis, using a technique under stereotactic conditions, can be considered a recent standard in favourable and intermediate risk disease. The postoperative irradiation technique, mainly indicated in cases of biochemical recurrence and lymph node involvement, is described in detail. Recommendations concerning contouring and dosimetry are also provided.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104777"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145614829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotherapy for primary lung cancer: 2025 update 原发性肺癌放疗：2025年更新

IF 1.4 4区医学 Q4 ONCOLOGY

Cancer Radiotherapie

Pub Date : 2025-11-01 DOI: 10.1016/j.canrad.2025.104779

Jonathan Khalifa , Yasmine El Houat , Sébastien Thureau , Julien Darréon , Delphine Antoni , Eivind Blais , Cécile Le Péchoux , Delphine Lerouge , Antonin Levy , François Lucia , Alexis Marguerit , Étienne Martin , Baptiste Pichon , Nicolas Pourel , Philippe Giraud , François-Georges Riet

Herein are presented the update of the recommendations from the Société française de radiothérapie oncologique (the French society for radiation oncology) regarding the indications and methods of lung cancer radiotherapy. The recommendations for delineation of the target volumes and organs at risk are detailed.

本文介绍了法国放射肿瘤学学会关于肺癌放射治疗的适应症和方法的最新建议。详细介绍了划定目标体积和有危险器官的建议。

引用次数: 0

Radiotherapy for oral cavity cancers: 2025 update 口腔癌放疗：2025年更新。

IF 1.4 4区医学 Q4 ONCOLOGY

Cancer Radiotherapie

Pub Date : 2025-11-01 DOI: 10.1016/j.canrad.2025.104771

Yasmine El Houat , Michel Lapeyre , Sophie Renard , Séverine Racadot , Laure Vieillevigne , Anouchka Modesto , Pierre Blanchard , Yoann Pointreau

Intensity-modulated conformal radiotherapy and brachytherapy are among the standard techniques for radiation treatments of oral cavity cancers. In this paper, each technique is detailed in terms of indications, treatment planning, volume delineation and selection, dosimetry, and position verification. This document represents an update of the Société française de radiothérapie oncologique (the French society for radiation oncology) guidelines (RecoRad™) for this anatomical site within the upper aerodigestive tract.

调强适形放疗和近距离放疗是口腔癌放射治疗的标准技术。在本文中，每种技术都详细介绍了适应症，治疗计划，体积划定和选择，剂量测定和位置验证。本文档是对法国放射肿瘤学学会（societyfranaise de radithrapie oncologique）指南（RecoRad™）的更新，该指南针对上气消化道内的该解剖部位。

引用次数: 0

Radiotherapy for penile cancers: 2025 update 放射治疗阴茎癌：2025年更新

IF 1.4 4区医学 Q4 ONCOLOGY

Cancer Radiotherapie

Pub Date : 2025-11-01 DOI: 10.1016/j.canrad.2025.104761

Geneviève Loos , Alexandre Escande , Sabrina Aziez , Vincent Marchesi , Paul Sargos , Mario Terzilli , Igor Latorzeff , Stéphane Supiot , Vérane Achard , Jennifer Le Guévelou , Aude Flechon , Jean-Michel Hannoun-Lévi , Cyrus Chargari

This article presents an update of the French national guidelines for the management of penile cancer, with recommendations on dose and volume for radiotherapy and brachytherapy. Multidisciplinary management and centralization in high-level of expertise centres is key for the management of this rare malignancy. For patients at high-risk of having micrometastatic disease (stage T1b or higher), a dynamic sentinel node biopsy should be offered as surgical staging and human papillomavirus status should be obtained. Organ-preservation with brachytherapy should be discussed whenever it is possible (tumours limited to the glans). For locoregionally advanced diseases, chemoradiotherapy as primary treatment could be discussed.

本文介绍了法国国家阴茎癌管理指南的更新，并推荐了放疗和近距离治疗的剂量和体积。多学科管理和集中在高水平的专家中心是关键的管理这种罕见的恶性肿瘤。对于具有微转移性疾病高风险的患者（T1b期或更高），应提供动态前哨淋巴结活检作为手术分期，并应获得人乳头瘤病毒状态。只要有可能（肿瘤局限于龟头），应讨论用近距离放射疗法保存器官。对于局部进展的疾病，可以讨论放化疗作为主要治疗方法。

引用次数: 0

Radiotherapy of bone metastases: 2025 update 骨转移的放疗：2025年更新

IF 1.4 4区医学 Q4 ONCOLOGY

Cancer Radiotherapie

Pub Date : 2025-11-01 DOI: 10.1016/j.canrad.2025.104769

Nicolas Martz , Jean Christophe Faivre , Guillaume Beldjoudi , Antoine Arnaud , Jérôme Chamois , Stéphane Supiot , Maximilien Rogé , Sébastien Thureau

We present the updated recommendations of the Société française de radiothérapie oncologique (the French society for radiation oncology) regarding the indications and technical modalities of radiotherapy for bone metastases. This treatment is commonly used in the management of patients with cancer. In most cases, it involves relatively simple radiotherapy technique with proven efficacy in reducing pain or managing spinal cord compression. More complex treatments using stereotactic conditions can be proposed for patients with painful bone metastases, oligometastatic disease, or in case of reirradiation. In this context, increased vigilance must be given to the risks of spinal cord toxicity.

我们提出了法国放射肿瘤学学会关于骨转移放射治疗的适应症和技术模式的最新建议。这种治疗方法通常用于治疗癌症患者。在大多数情况下，它涉及相对简单的放疗技术，在减轻疼痛或处理脊髓压迫方面已被证明有效。对于疼痛骨转移、少转移性疾病或再照射的患者，可以建议使用立体定向条件进行更复杂的治疗。在这种情况下，必须提高对脊髓毒性风险的警惕。

引用次数: 0

Role of radiotherapy in the management of anal canal cancer: Recommendations of the Société française de radiothérapie oncologique 放射治疗在肛管癌治疗中的作用：放射与肿瘤学会的建议

IF 1.4 4区医学 Q4 ONCOLOGY

Cancer Radiotherapie

Pub Date : 2025-11-01 DOI: 10.1016/j.canrad.2025.104770

Charles Raynaud , Maria Jolnerovski , Claire Lemanski , Benjamin Schipman , Laurence Moureau-Zabotto , Igor Bessières , Florence Huguet , Véronique Vendrely

We present the updated recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) regarding the use of external beam radiotherapy and brachytherapy in the management of anal cancer. Anal cancer is a rare malignancy with an increasing incidence, largely due to the high prevalence of Human papillomavirus infection. It primarily affects females over 65 years of age. The most common histological type is squamous cell carcinoma. The standard treatment involves a combination of intensity-modulated radiotherapy and concurrent chemotherapy with 5-fluorouracil (or capecitabine) and mitomycin. A localized boost dose to the tumour can be delivered either by external beam radiotherapy or brachytherapy. Recent studies have demonstrated that intensity-modulated radiotherapy helps avoid treatment interruptions, which are considered detrimental to efficacy. However, while radiotherapy achieves good outcomes for T1-T2 tumours without nodal involvement, T3-T4 stages or tumours with nodal involvement are associated with a poorer prognosis. Therefore, concomitant chemotherapy (5-fluorouracil or capecitabine with mitomycin) is recommended for tumours greater than 3 cm or those with nodal invasion. This approach remains a topic of debate for early-stage tumours. Target volumes, organs at risk delineation, doses, and fractionation regimens are discussed with respect to the balance between treatment efficacy and toxicity. Follow-up recommendations are provided to ensure early detection of cancer recurrence and late treatment-related side effects.

我们提出来自法国放射肿瘤学学会（SFRO）关于在肛门癌治疗中使用外束放疗和近距离放疗的最新建议。肛门癌是一种发病率越来越高的罕见恶性肿瘤，主要是由于人类乳头瘤病毒感染的高流行率。它主要影响65岁以上的女性。最常见的组织学类型是鳞状细胞癌。标准治疗包括强度调节放疗和5-氟尿嘧啶（或卡培他滨）和丝裂霉素联合化疗。局部增强剂量可以通过外部放射治疗或近距离治疗给予肿瘤。最近的研究表明，调强放疗有助于避免治疗中断，而治疗中断被认为对疗效有害。然而，放疗对于T1-T2期无淋巴结受累的肿瘤效果良好，而T3-T4期或有淋巴结受累的肿瘤预后较差。因此，对于大于3cm的肿瘤或有淋巴结侵袭的肿瘤，建议联合化疗（5-氟尿嘧啶或卡培他滨联合丝裂霉素）。这种方法对于早期肿瘤仍然是一个有争议的话题。靶体积，器官的危险描绘，剂量和分离方案的讨论，关于治疗效果和毒性之间的平衡。提供随访建议，以确保早期发现癌症复发和晚期治疗相关的副作用。

{"title":"Role of radiotherapy in the management of anal canal cancer: Recommendations of the Société française de radiothérapie oncologique","authors":"Charles Raynaud , Maria Jolnerovski , Claire Lemanski , Benjamin Schipman , Laurence Moureau-Zabotto , Igor Bessières , Florence Huguet , Véronique Vendrely","doi":"10.1016/j.canrad.2025.104770","DOIUrl":"10.1016/j.canrad.2025.104770","url":null,"abstract":"<div><div>We present the updated recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) regarding the use of external beam radiotherapy and brachytherapy in the management of anal cancer. Anal cancer is a rare malignancy with an increasing incidence, largely due to the high prevalence of Human papillomavirus infection. It primarily affects females over 65years of age. The most common histological type is squamous cell carcinoma. The standard treatment involves a combination of intensity-modulated radiotherapy and concurrent chemotherapy with 5-fluorouracil (or capecitabine) and mitomycin. A localized boost dose to the tumour can be delivered either by external beam radiotherapy or brachytherapy. Recent studies have demonstrated that intensity-modulated radiotherapy helps avoid treatment interruptions, which are considered detrimental to efficacy. However, while radiotherapy achieves good outcomes for T1-T2 tumours without nodal involvement, T3-T4 stages or tumours with nodal involvement are associated with a poorer prognosis. Therefore, concomitant chemotherapy (5-fluorouracil or capecitabine with mitomycin) is recommended for tumours greater than 3cm or those with nodal invasion. This approach remains a topic of debate for early-stage tumours. Target volumes, organs at risk delineation, doses, and fractionation regimens are discussed with respect to the balance between treatment efficacy and toxicity. Follow-up recommendations are provided to ensure early detection of cancer recurrence and late treatment-related side effects.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104770"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reirradiation of prostate, gynaecologic and pelvic tumours, suggestions from the Recommendations Commission of the Société française de radiothérapie oncologique 前列腺、妇科和盆腔肿瘤的再照射，来自放射肿瘤学会建议委员会的建议。

IF 1.4 4区医学 Q4 ONCOLOGY

Cancer Radiotherapie

Pub Date : 2025-11-01 DOI: 10.1016/j.canrad.2025.104778

Yuedan Zhou , Alexandre Escande , David Pasquier , Cyrus Chargari , Myriam Ayadi , Jonathan Khalifa , Delphine Antoni , Igor Latorzeff , Valentine Guimas , Véronique Vendrely , Arnaud Beddok , Stéphane Supiot

The process of reirradiation in oncology presents a distinctive set of challenges, wherein clinical decision-making is predicated on a delicate balancing act between the efficacy of the treatment and the risk of severe toxicity. Despite the paucity of randomized and prospective data, an increasing number of clinical guidelines encourage its consideration for patients with local or metastatic recurrence. While awaiting dedicated guidance from international scientific societies, the following publication is based on the guidelines and multicentre reflections of the Recommendations Commission of the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology). It addresses key questions related to reirradiation, with a particular focus on prostate, gynaecological and pelvic tumours.

肿瘤学中的再照射过程呈现出一系列独特的挑战，其中临床决策是基于治疗效果和严重毒性风险之间的微妙平衡。尽管缺乏随机和前瞻性数据，但越来越多的临床指南鼓励将其用于局部或转移性复发患者。在等待国际科学学会提供专门指导的同时，以下出版物是根据法国放射肿瘤学学会（SFRO）建议委员会的指导方针和多中心思考编写的。它解决了与再照射有关的关键问题，特别关注前列腺、妇科和盆腔肿瘤。

{"title":"Reirradiation of prostate, gynaecologic and pelvic tumours, suggestions from the Recommendations Commission of the Société française de radiothérapie oncologique","authors":"Yuedan Zhou , Alexandre Escande , David Pasquier , Cyrus Chargari , Myriam Ayadi , Jonathan Khalifa , Delphine Antoni , Igor Latorzeff , Valentine Guimas , Véronique Vendrely , Arnaud Beddok , Stéphane Supiot","doi":"10.1016/j.canrad.2025.104778","DOIUrl":"10.1016/j.canrad.2025.104778","url":null,"abstract":"<div><div>The process of reirradiation in oncology presents a distinctive set of challenges, wherein clinical decision-making is predicated on a delicate balancing act between the efficacy of the treatment and the risk of severe toxicity. Despite the paucity of randomized and prospective data, an increasing number of clinical guidelines encourage its consideration for patients with local or metastatic recurrence. While awaiting dedicated guidance from international scientific societies, the following publication is based on the guidelines and multicentre reflections of the Recommendations Commission of the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology). It addresses key questions related to reirradiation, with a particular focus on prostate, gynaecological and pelvic tumours.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104778"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145607879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotherapy guidelines for gliomas: 2025 update 胶质瘤放疗指南：2025年更新

IF 1.4 4区医学 Q4 ONCOLOGY

Cancer Radiotherapie

Pub Date : 2025-11-01 DOI: 10.1016/j.canrad.2025.104774

Delphine Antoni , Emmanuel Mesny , Osman El Kabbaj , Charlotte Robert , Kévin Quintin , Loïc Feuvret , Julian Biau , Julian Jacob

Gliomas are the most frequent malignant primary brain tumours in adults. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, Karnofsky performance status) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiotherapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential; they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the Société française de radiothérapie oncologique (the French Society for Radiation Oncology) on the indications and the technical procedures for performing radiotherapy in patients with gliomas.

胶质瘤是成人最常见的恶性原发性脑肿瘤。在选择放射治疗的剂量和技术时，必须考虑到胶质瘤的危险器官的邻近性、浸润性和放射耐药性。胶质瘤患者的治疗是基于临床因素（年龄，Karnofsky性能状态）和肿瘤特征（组织学，分子生物学，肿瘤位置），并强烈依赖于可用的和相关的治疗，如手术，放疗和化疗。分子生物标志物的知识目前是必不可少的；它们越来越多地成为促进诊断和治疗决策的附加因素。我们提出了法国放射肿瘤学学会关于胶质瘤患者放射治疗的适应症和技术程序的最新建议。

引用次数: 0

Radiotherapy for lung metastases 放射治疗肺转移。

IF 1.4 4区医学 Q4 ONCOLOGY

Cancer Radiotherapie

Pub Date : 2025-11-01 DOI: 10.1016/j.canrad.2025.104760

Antonin Levy , Marion Tonneau , Julien Darréon , Jonathan Khalifa , Delphine Antoni , Eivind Blais , Cécile Le Péchoux , Delphine Lerouge , François Lucia , Alexis Marguerit , Étienne Martin , Baptiste Pichon , Nicolas Pourel , François-Georges Riet , Philippe Giraud , Sébastien Thureau

Pulmonary metastases are a common site of spread for many cancers, regardless of the primary tumour. While systemic treatments remain the standard of care, local therapies, particularly stereotactic body radiotherapy, have shown promising results in terms of local control and survival in selected patients with oligometastatic disease. This document presents the updated recommendations from the Société française de radiothérapie oncologique (SFRO, French society for radiation oncology) regarding the indications and technical aspects of radiotherapy for intrapulmonary metastases. The focus is on stereotactic body radiotherapy, including patient selection criteria, prescription protocols, treatment planning, respiratory motion management, and organ-at-risk constraints. Alternative approaches, such as moderately hypofractionated palliative radiotherapy, are also discussed for cases where stereotactic body radiotherapy is not feasible. These recommendations aim to guide clinical practice and promote the safe and effective use of high-precision radiotherapy for pulmonary metastases.

肺转移是许多癌症的常见扩散部位，与原发肿瘤无关。虽然全身治疗仍然是标准的治疗方法，但局部治疗，特别是立体定向放射治疗，在局部控制和选定的少转移性疾病患者的生存方面显示出有希望的结果。本文件介绍了法国放射肿瘤学学会（SFRO）关于肺内转移放射治疗的适应症和技术方面的最新建议。重点是立体定向体放射治疗，包括患者选择标准、处方方案、治疗计划、呼吸运动管理和器官危险限制。替代方法，如中度低分割姑息放疗，也讨论了立体定向放射治疗不可行的情况下。这些建议旨在指导临床实践，促进高精度放射治疗在肺转移中的安全有效应用。

{"title":"Radiotherapy for lung metastases","authors":"Antonin Levy , Marion Tonneau , Julien Darréon , Jonathan Khalifa , Delphine Antoni , Eivind Blais , Cécile Le Péchoux , Delphine Lerouge , François Lucia , Alexis Marguerit , Étienne Martin , Baptiste Pichon , Nicolas Pourel , François-Georges Riet , Philippe Giraud , Sébastien Thureau","doi":"10.1016/j.canrad.2025.104760","DOIUrl":"10.1016/j.canrad.2025.104760","url":null,"abstract":"<div><div>Pulmonary metastases are a common site of spread for many cancers, regardless of the primary tumour. While systemic treatments remain the standard of care, local therapies, particularly stereotactic body radiotherapy, have shown promising results in terms of local control and survival in selected patients with oligometastatic disease. This document presents the updated recommendations from the Société française de radiothérapie oncologique (SFRO, French society for radiation oncology) regarding the indications and technical aspects of radiotherapy for intrapulmonary metastases. The focus is on stereotactic body radiotherapy, including patient selection criteria, prescription protocols, treatment planning, respiratory motion management, and organ-at-risk constraints. Alternative approaches, such as moderately hypofractionated palliative radiotherapy, are also discussed for cases where stereotactic body radiotherapy is not feasible. These recommendations aim to guide clinical practice and promote the safe and effective use of high-precision radiotherapy for pulmonary metastases.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104760"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145508525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Cancer Radiotherapie

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀